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Abstract
Background: It is uncertain that chronic heart failure (CHF) patients are susceptible
to renal tubular damage with that of worsening renal function (WRF) preceding clini-
cal outcomes.
Hypothesis: Changes in tubular damage biomarkers are stronger predictors of subse-
quent clinical events than changes in creatinine (Cr), and both have different clinical
determinants.
Methods: During 2.2 years, we repeatedly simultaneously collected a median of
9 blood and 8 urine samples per patient in 263 CHF patients. We determined the
slopes (rates of change) of the biomarker trajectories for plasma (Cr) and urinary
tubular damage biomarkers N-acetyl-β-D-glucosaminidase (NAG), and kidney-injury-
molecule (KIM)-1. The degree of tubular injury was ranked according to NAG and
KIM-1 slopes: increase in neither, increase in either, or increase in both; WRF was
defined as increasing Cr slope. The composite endpoint comprised HF-hospitaliza-
tion, cardiac death, left ventricular assist device placement, and heart transplantation.
Results: Higher baseline NT-proBNP and lower eGFR predicted more severe tubular
damage (adjusted odds ratio, adj. OR [95%CI, 95% confidence interval] per doubling
NT-proBNP: 1.26 [1.07-1.49]; per 10 mL/min/1.73 m2 eGFR decrease 1.16
[1.03-1.31]). Higher loop diuretic doses, lower aldosterone antagonist doses, and
higher eGFR predicted WRF (furosemide per 40 mg increase: 1.32 [1.08-1.62]; spi-
ronolactone per 25 mg decrease: 1.76 [1.07-2.89]; per 10 mL/min/1.73 m2 eGFR
increase: 1.40 [1.20-1.63]). WRF and higher rank of tubular injury individually
entailed higher risk of the composite endpoint (adjusted hazard ratios, adj. HR [95%
CI]: WRF 1.9 [1.1-3.4], tubular 8.4 [2.6-27.9]; when combined risk was highest 15.0
[2.0-111.0]).
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Conclusion: Slopes of tubular damage and WRF biomarkers had different clinical
determinants. Both predicted clinical outcome, but this association was stronger for
tubular injury. Prognostic effects of both appeared independent and additive.
K E YWORD S
cardiorenal interaction, heart failure, tubular damage biomarkers, tubular injury, worsening
renal function
1 | INTRODUCTION
Renal dysfunction is the most prevalent comorbidity among patients with
chronic heart failure (CHF) and is strongly associated with clinical out-
comes such as heart failure (HF) hospitalization and mortality.1-4 Under-
lying hemodynamic dependence between the heart and the kidneys is
widely considered as the main driver of the cardiorenal interaction lead-
ing to adverse outcomes.5 However, other biochemical, neurohumoral,
metabolic, and immunological derangements also occur during the
organs' interplay, which has led to the definition of the cardiorenal syn-
drome (CRS).6,7 Because renal dysfunction entails such a poor prognosis
in CHF, attention has focused on identifying the signals along the cardio-
renal axis that precede adverse outcomes.8 However, the mechanisms
and the chronology according to which the failing heart damages-specific
renal structures that lead to CRS are poorly understood.9
Decreased baseline renal function is clearly important, but wors-
ening renal function (WRF) quantified as creatinine (Cr) increase over
time has been shown to be an even more prominent predictor of
adverse outcome in CHF.1 We have recently confirmed and extended
these findings by using frequent repeated renal function assessments
in CHF patients.4 In the setting of CHF, WRF may be due to several
factors. For example, it may be just temporally reduced due to hemo-
dynamic changes, but it may also be due to permanently reduced renal
function from nephron loss.
Renal tubular damage is present in CHF patients due to
tubulointerstitial injury by renal tissue hypoperfusion or due to a
damaged glomerular filtration barrier.10-12 Studies have shown that
higher levels of urinary tubular damage markers N-acetyl-β-D-
glucosaminidase and kidney injury molecule (KIM)-1 entailed poor
prognosis in CHF independently of eGFR.4,12 Therefore, markers of
renal tubular damage may reflect another pathway for renal alter-
ations in the milieu of the CRS.
To investigate the degree of tubular injury, we used well-
validated urinary markers13,14 such as NAG and KIM-1 qualified as
the biomarker for kidney toxicity in preclinical settings by the
U.S. Food and Drug Administration and European Medicines
Agency.15,16 These urinary markers can both detect and quantify the
degree of tubular injury providing discrimination of histopathological
severity of the tubular damage caused by both ischemic injury and
nephrotoxins.16-18
There is a potential for simultaneous biomarker-based monitoring
of renal function and tubular status to improve the management of
CHF patients during their follow-up.
2 | MATERIAL AND METHODS
The serial biomarker measurements and new echocardiographic tech-
niques in chronic heart failure patients result in tailored prediction of
prognosis (Bio-SHiFT) is a prospective cohort of stable patients with
CHF, conducted in Erasmus Medical Center, Rotterdam, and
Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands. Patients
were included if aged ≥18 years and if CHF had been diagnosed
≥3 months ago according to the European Society of Cardiology
guidelines (for details, see Figure S1).19 Patients were ambulatory and
stable, that is, they had not been hospitalized for HF in the past
3 months. The study was approved by the medical ethics committees,
conducted in accordance with the Declaration of Helsinki, and regis-
tered in ClinicalTrials.gov (NCT01851538). Written informed consent
was obtained from all patients. This investigation comprised 263 stable
patients with CHF, who were enrolled during the first inclusion period
(October 2011 to June 2013) and completed their follow-up in 2015.
Since 95% of the study population had heart failure with reduced
ejection fraction (HFrEF), in this study, we focused on the HFrEF
patients (n = 250).
All patients were evaluated by research physicians, who collected
information on HF-related symptoms, New York Heart Association
class (NYHA) class, and performed a physical examination and col-
lected samples. Information on HF etiology, ejection fraction, cardio-
vascular risk factors, comorbidities, and treatment were retrieved
from hospital records. Study follow-up visits were predefined and
scheduled tri-monthly (±1 month), with a maximum of 10 study
follow-up visits. All patients were also routinely followed at the outpa-
tient clinic by treating physicians who were blinded for biomarker
data. Occurrence of rehospitalizations for HF, myocardial infarction
(MI), percutaneous coronary intervention (PCI), coronary artery bypass
grafting (CABG), arrhythmias, cerebrovascular accident (CVA), cardiac
transplantation, left ventricular assist device (LVAD)-placement, and
mortality was recorded in electronic case-report forms, and associated
hospital records and discharge letters were collected. A clinical event
committee, blinded for biomarker data, reviewed hospital records and
discharge letters, and adjudicated the study endpoints.
The composite endpoint comprised cardiac death, cardiac trans-
plantation, LVAD implantation, and hospitalization for the manage-
ment of acute or worsened HF, whichever occurred first. Cardiac
death was defined as death from MI or other ischemic heart disease
(implantable cardioverter defibrillator (ICD)-10: I20-I25), death from
other heart disease including HF (I30-I45 and I47-I52), sudden cardiac
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TABLE 1 Patient characteristics stratified by NAG and KIM-1 slopes
NAG and KIM-1 stable/
decreased (n = 66)
NAG or KIM-1
increased (n = 104)
NAG and KIM-1
increased (n = 80) P-value
Clinical features
Age (years) 65 (57-72) 68 (60-77) 70 (60-80) .016*
Men 48 (73) 77 (74) 59 (74) .90
Ischemic etiology 27 (41) 48 (46) 41 (51) .21
BMI kg/m2 27.4 (25.1-30.9) 26.2 (24.0-30.0) 26.3 (24.2-30.2) .39
Heart rate b.p.m. 66 (60-74) 66 (59-71) 69 (60-76) .16
SBP mmHg 121 (110-134) 120 (105-140) 120 (108-130) .69
DBP mmHg 74 (61-82) 74 (64-80) 70 (60-78) .05
Congestiona 37 (56) 68 (65) 52 (65) .29
NYHA III/IV 9 (14) 23 (22) 30 (38) .001*
CRT 26 (39) 34 (33) 18 (23) .027*
Echocardiographic featuresb
LVEF 31 (26-40) 30 (23-35) 28 (20-35) .03*
DiasLVD 62 (56-67) 64 (57-72) 65 (57-74) .06
SysLVD 49 (42-56) 51 (42-59) 53 (43-62) .07
E/A ratio 0.7 (0.6-1.1) 1.0 (0.7-1.4) 0.9 (0.6-1.9) .06
E/E0 ratio 9.7 (6.3-13.0) 10.9 (6.6-17.4) 11.4 (7.1-19.2) .25
Medical history
Prior MI 22 (33) 39 (38) 34 (43) .25
Atrial fibrillation 23 (35) 43 (41) 31 (39) .66
Diabetes 14 (21) 31 (30) 32 (40) .014*
Hypertension 26 (39) 47 (45) 40 (50) .20
COPD 8 (12) 10 (10) 13 (16) .41
Medication prevalence (%)/average total daily dose (mg)c
Beta-blocker 96%/45 mg 91%/41 mg 84%/47 mg .30d
ACE-I/ARBs 96%/24 mg 93%/25 mg 94%/24 mg .96d
Loop diuretics 85%/77 mg 90%/78 mg 96%/97 mg .15d
MRAs 74%/23 mg 70%/23 mg 65%/23 mg .96d
Cardiac biomarkers
NT-proBNP ng/L 578 (153-1680) 1076 (378-2148) 1682 (866-3529) <.001*
cTnT ng/L 12.4 (7.5-24.8) 16.9 (9.4-32.4) 22.6 (13.7-43.3) <.001*
Renal glomerular indices (plasma)
Creatinine mg/dL 1.10 (0.92-1.26) 1.17 (0.97-1.43) 1.33 (1.04-1.77) <.001*
eGFRmL/min/1.73 m
2 70 (51-79) 58 (44-76) 50 (36-72) <.001*
eGFR<60 21 (32) 57 (55) 52 (65) <.001*
Renal tubular markers (urine)
NAG U/gCr 5.1 (2.7-10.0) 5.7 (3.9-9.1) 6.7 (4.6-9.2) .11
KIM-1 ng/gCr 452 (238-930) 485 (243-882) 555 (256-973) .45
Note: For reasons of uniformity continuous variables are presented as medians (25th-75th percentiles) and categorical variables are presented as n (%); P-
values signify trend across groups and the asterisk indicates P < .05.
Abbreviations: ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; A, peak late filling velocity; BMI, Body mass index;
COPD, chronic obstructive pulmonary disease CRP, C-reactive protein; cTnT, cardiac troponin T; CVA, cerebrovascular accident; DBP, Diastolic blood
pressure; DiasLVD, diastolic left ventricular diameter; E, peak early filling velocity; E0 , early diastolic mitral annular velocity; eGFR, estimated glomerular
filtration rate; KIM-1, kidney injury molecule-1; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NAG, N-acetyl-β-D-
glucosaminidase; NYHA class, New York Heart Association class; SBP, Systolic blood pressure; SysLVD, systolic left ventricular diameter; TIA, transitory
ischemic attack.
aCongestion was considered present if ≥2 symptoms or signs were present at baseline (dyspnea, orthopnea, fatigue, elevated jugular venous pressure,
presence of rales/crackles and pedal oedema).
bBecause of logistic reasons, baseline LVEF, DiasLVD, and SysLVD were available in 74%, E/A ratio in 62%, and E/E0 ratio in 69% of all HFrEF patients.
cTable S3 shows the conversion factors for calculation of total daily dose equivalents of different HF medications.
dP-value for the difference in average total daily dose.
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death (I46), sudden death undefined (R96), or unwitnessed or ill-
described death (R98, R99). Hospitalization for acute or worsened HF
was defined as a hospitalization for an exacerbation of HF symptoms,
in combination with two of the following: BNP or NT-proBNP >3
times the upper limit of normal, signs of worsening HF, such as
pulmonary rales, raised jugular venous pressure or peripheral edema,
increased dose or intravenous administration of diuretics, or adminis-
tration of positive inotropic agents.19
Blood and urine samples were collected at baseline and during
study visits, and were processed and stored at −80C. Laboratory
TABLE 2 Patient characteristics stratified by creatinine slope
Creatinine stable/decreased (n = 104) Creatinine increased (n = 146) P-valuea
Clinical features
Age years 66 (57-74) 68 (60-77) .18
Men 73 (70) 111 (76) .30
Ischemic etiology 45 (43) 71 (49) .40
BMI kg/m2 26.6 (24.1-30.2) 26.8 (24.4-30.2) .83
Heart rate b.p.m. 68 (59-77) 65 (60-72) .33
SBP mmHg 121 (110-136) 120 (106-132) .26
DBP mmHg 75 (65-80) 70 (60-80) .08
Congestion* 67 (64) 90 (62) .65
NYHA III/IV 29 (28) 33 (23) .34
CRT 35 (34) 43 (30) .48
Echocardiographic featuresb
LVEF 31 (23-40) 29 (23-36) .20
DiasLVD 64 (56-71) 64 (59-72) .47
SysLVD 47 (41-58) 52 (45-60) .043*
E/A ratio 0.8 (0.6-1.3) 0.9 (0.6-1.3) .20
E/E0 ratio 9.6 (5.8-13.3) 11.8 (7.9-19.0) .010*
Medical history
Prior MI 32 (31) 63 (43) .047*
Atrial fibrillation 35 (34) 62 (43) .16
Diabetes 27 (26) 50 (34) .16
Hypertension 41 (39) 72 (49) .12
COPD 9 (9) 22 (15) .13
Medication prevalence (%)/average total daily dose (mg)
Beta-blocker 89%/48 mg 91%/41 mg .32
ACE-I/ARBs 96%/23 mg 93%/25 mg .21
Loop diuretics 89%/63 mg 93%/98 mg .003*
MRAs 71%/25 mg 69%/21 mg .022*
Cardiac biomarkers
NT-proBNP ng/L 894 (279-2158) 1369 (514-2871) .042*
cTnT ng/L 14.3 (8.3-29.4) 20.1 (10.7-38.1) .018*
Renal glomerular indices (plasma)
Creatinine mg/dL 1.32 (1.08-1.67) 1.10 (0.92-1.38) <.001*
eGFRmL/min/1.73 m
2 51 (37-71) 65 (48-82) <.001*
eGFR<60 66 (64) 64 (44) .002*
Renal tubular markers (urine)
NAG, U/gCr 5.5 (3.4-8.5) 6.5 (3.9-9.3) .06
KIM-1, ng/gCr 467 (244-828) 505 (247-995) .21
Note: For description, please see Table 2; P-values signify a trend across groups and the asterisk indicates P < .05.
ap-value for the difference in the average total daily dose.
bBecause of logistic reasons, baseline LVEF, DiasLVD, and SysLVD were available in 74%, E/A ratio in 62%, and E/E0 ratio in 69% of all HFrEF patients.
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personnel was blinded for clinical data. Batch analysis of serum was
performed at Erasmus Medical Center: NT-proBNP was analyzed
using an electrochemiluminescence immunoassay (Roche Diagnos-
tics, Elecsys 2010, Indianapolis, Indiana), cardiac troponin T was also
measured using an electrochemiluminescence immunoassay (Roche
Diagnostics, Elecsys 2010 immunoassay analyzer). Plasma and urine
samples were transported at −80C to HaemoScan BV, Groningen,
the Netherlands for batch analysis. Creatinine was determined by a
colorimetric test by the Jaffé reaction. Plasma was used undiluted,
and urine was diluted 10 times in water (lower limit of detection
(LLD): plasma 0.14 mg/dL, urine: 1.56 mg/mL). KIM-1 was deter-
mined in urine diluted 50% in 0.1% BSA/PBS buffer, by ELISA (R&D
systems, Minneapolis, Minnesota) (LLD: 0.146 ng/mL). NAG was
determined using a substrate p-nitrophenyl N-acetyl-β-D-
glucosaminidase at pH 4.5 (Sigma, St Louis, Missouri) (LLD: 0.485 U/
L). All urinary biomarkers were normalized to urinary Cr concentra-
tions to correct for concentration or dilution of urine. The glomerular
filtration rate (GFR) was determined by the Chronic Kidney Disease
Epidemiology Collaboration equation that has been validated in HF
patients20 and categorized using K/DOQI guidelines.21
To assess patient-specific slopes (rates of change over time) of
biomarker trajectories, we performed joint modeling (JM) of linear
mixed-effects (LME) and Cox regression models.22 The LME models
estimate the individual biomarker trajectory based on repeated mea-
surements and also correct for biomarkers' sampling variability (for
details, see Figure S2).23 The JM then combines LME with the Cox
regression model to adjust the biomarker trajectory for different
follow-up durations between patients.23 The degree of tubular injury
was ordered according to the slopes of tubular damage biomarkers:
increase in neither, increase in either, and increase in both; WRF was
defined as increasing Cr slope.
For continuous variables, the presence of a linear trend across
different categories of renal tubular damage and WRF was assessed
by analysis of variance or the Kruskal‑Wallis test and categorical vari-
ables were tested by the χ2 trend test. Covariates that were uni-
variably associated with tubular damage or WRF (exploratory P < .10)




Renal tubular damage (dependent
variable)a
NT-proBNP (per doubling) 1.26 (1.07-1.49) P = .006
eGFR (per 10 mL/min/1.73 m2 decrease) 1.16 (1.03-1.32) P = .015
WRF (dependent variable)c
Loop diuretics (per 40 mg furosemide
equivalent. dose increase)
1.30 (1.07-1.59) P = .010
MRAs (per 25 mg spironolactone
equivalent. dose decrease)
1.85 (1.10-3.09) P = .019
eGFR (per 10 mL/min/1.73 m2 decrease) 0.73 (0.63-0.85) P < .001
Note: OR indicates odds ratio for having a more severe tubular damage or
WRF; 95%CI indicates 95% confidence interval for the corresponding OR;
eGFR indicates estimated glomerular filtration rate, MRAs indicates
mineralocorticoid receptor antagonists.
aCovariates that were found to be different across categories of tubular
damage with P < .10 (see Table 1) were entered into a multivariable ordi-
nal regression model and those were: age, NYHA class, diabetes, use of
cardiac resynchronization therapy (CRT), diastolic blood pressure, NT-
proBNP, cTnT, and eGFR.
b*Represents only covariates with P-value <.05 were presented in the
table.
cCovariates that were found to be different between WRF patient and
non-WRF patients with P < .10 (see Table 2) were entered into a
multivariable binary regression model and those were: diastolic blood
pressure, NT-proBNP, hs-cTnT, eGFR, urinary NAG, prior myocardial
infarction, loop diuretics and MRAs doses.
F IGURE 1 Distributions of slopes of renal biomarkers prior to
study endpoints. Notes: X-axis displays number of patients who
experienced the event (red) and those who did not (blue), Y-axis
displays the estimated slopes on the continuous scale, where positive
numbers correspond to increasing slopes and negative numbers
correspond to decreasing slopes. t test was used test the average
difference between patient with and without event
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F IGURE 2 Legend on next page.
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were entered into a multivariable logistic regression model applying
proportional odds ordinal regression or binary logistic regression.
To investigate endpoint-free rates, we used the two-sided Breslow
test and the Breslow method to estimate event-time distributions. The
Cox regression model was performed to assess hazard ratios (HR) with
95% confidence intervals (95%CI) for study endpoints.
Statistical adjustments were performed by using biomarkers of
interest plus age, sex, diabetes, atrial fibrillation, NYHA class, diuretics,
systolic blood pressure, estimated glomerular filtration rate (eGFR)
(only for tubular damage markers), and biomarkers of myocardial
stretch and damage NT-proBNP and hs-cTnT.
Data on all variables were complete, except for systolic blood
pressure, which was missing in <5% of patients and for which imputa-
tions were applied using patients' clinical and outcome data.
All tests were two-tailed and P-values <.05 were considered sta-
tistically significant. All analyses were performed with SPSS (SPSS
25.0; IBM Corp., Armonk, NewYork),24 and R25 using the package
JMbayes.26
3 | RESULTS
Table S1 summarizes the baseline characteristics of the 250 HFrEF
patients. During a median of 2.2 (IQR: 1.4-2.5) years, we collected a
median of nine blood 5-10 and eight urine 5-10 samples per patient.
Table 1 shows that patients with greater tubular damage during
follow-up, had higher baseline NT-proBNP, cardiac troponin-T, and Cr
levels (ie, lower eGFR); lower left ventricular (LV) ejection fraction, more
frequently diabetes, NYHA class III/IV, and cardiac resynchronization
therapy (CRT), and were older. After multivariable adjustments, higher
baseline NT-proBNP and lower eGFR remained independent predictors
of more severe tubular damage (per doubling of NT-proBNP adjusted
odds ratio, adj. OR, 1.26 [95%CI 1.07-1.49], P = .006; and per
10 mL/min/1.73 m2 eGFR decrease 1.16 [1.03-1.32], P = .015) (Table 3).
Table 2 shows that patients with Cr incline during follow-up had
higher baseline NT-proBNP, cardiac troponin-T and higher eGFR,
higher systolic LV diameter, and E/E' ratio, more frequently a history
of myocardial infarction, and were on higher loop diuretic doses and
lower mineralocorticoid receptor antagonist (MRA) doses. After multi-
variable adjustments, higher eGFR levels and higher loop diuretic
doses, and lower MRA doses, remained independent predictors of Cr
incline (per 10 mL/min/1.73 m2 eGFR decrease: OR 0.73 [95%CI:
0.63-0.85], P < .001; per 40 mg furosemide equivalent dose increase:
1.30 [1.07-1.59], P = .010; and per 25 mg spironolactone equivalent
dose decrease: 1.85 [1.10-3.09], P = .019) (Table 3).
Of the 250 HFrEF patients, 66 (26%) reached the endpoint:
53 patients were rehospitalized for acute or worsened HF, 8 died of
cardiovascular causes, 2 underwent LVAD-placement, and 3 underwent
heart transplantation. Figure 1 shows that patients who experienced
the endpoint had significantly higher slopes of urinary NAG than
endpoint-free patients (mean ± SD: 0.27 ± 0.28 vs −0.02 ± 0.27
ln[U/gCr]/year, P < .001) and KIM-1 (0.22 ± 0.36 vs −0.05 ± 0.24
ln[ng/gCr]/year, P < .001), and plasma Cr (0.20 ± 0.35 vs 0.01 ±
0.17 ln[mg/dL]/year, P < .001). Lower baseline eGFR was positively
associated with greater tubular damage but inversely associated
with WRF during follow-up (Table S2).
Seventy-four percentage of HFrEF patients experienced incline
in either tubular damage biomarker during follow-up. Of those, 44%
of patients had both tubular biomarkers rising prior to the endpoint
or last sampling moment. Figure 2A shows that endpoint-free rates
were lowest when both tubular damage biomarkers were increased,
followed by the rates when either marker was increasing (P for
trend <.001). HR were almost four times higher in patients in whom
either tubular damage marker was increasing and eight times higher
if both were increasing during follow-up (NAG or KIM-1 slope
increased: adjusted hazard ratios, adj. HR 3.7 [95%CI: 1.1-12.6],
P = .034; NAG and KIM-1 slopes increased: 8.4 [2.6-27.9],
P < .001). These estimates were independent of the patients' clinical
characteristics, baseline eGFR, and cardiac biomarkers (NT-proBNP
and troponin T).
Fifty-eight percent of HFrEF patients experienced incline in Cr
levels during follow-up. Figure 2B shows that patients with increasing
plasma Cr slope had lower endpoint-free rates than their counterparts
(P = .018). The HR in these patients were also significantly higher than
in those in whom Cr remained stable or decreased (adj. HR 1.9
[1.1-3.4], P = .027).
Eighteen percent of HFrEF patients experienced deteriorating pat-
terns of both urinary tubular biomarkers as well as Cr, while 31% of
patients had at least one tubular biomarker rising without a change in Cr,
and only 10% of patients had neither biomarker worsening during
follow-up (for details, see Figure 2C). Figure 2C displays that when tubu-
lar damage markers were stable or improving, Cr incline did not affect
endpoint-free rates. However, if either NAG or KIM-1 slope increased,
endpoint-free rates decreased. Finally, the lowest endpoint-free rates
were in patients who had increasing slopes of all three renal biomarkers
(P for trend <.001).
F IGURE 2 Kaplan–Meier survival curves stratified by slopes of renal biomarkers. Notes: Shown are Kaplan–Meier (KM) curves for the cumulative
event-free survival of the composite of HF-rehospitalization, cardiac death, LVAD placement, and heart transplantation. A, KM curves are stratified by
whether both NAG and KIM-1 slopes were decreasing/stable (blue); either NAG or KIM-1 slope was increasing (red); or both NAG and KIM-1 slopes were
increasing (green); B, KM curves are stratified by whether Cr slope was decreasing/stable (blue) or increasing (red). C, KM curves are stratified by whether
slopes of all three renal biomarkers were decreasing/stable (blue); NAG and KIM-1 slopes were decreasing/stable, but creatinine slope was increasing
(red); either NAG or KIM-1 slope was increasing but creatinine slope was decreasing/stable (green); either NAG or KIM-1 slope was increasing, and
creatinine slope was increasing (orange); and slopes of all three biomarkers were increasing (purple). Hazard ratios (HR) were adjusted for age, sex,
diabetes, atrial fibrillation, NYHA class, diuretics, systolic blood pressure, eGFR (only for tubular damage biomarkers), NT-proBNP, and hs-cTnT
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4 | DISCUSSION
To our best knowledge, this study is the first to identify clinical deter-
minants of progressive renal tubular damage in CHF. Of note, these
determinants differ from those found for WRF, which strengthens the
recommendation that glomerular and tubular compartment should be
jointly assessed. This study also displays that patients in whom both
renal compartments deteriorate during outpatient follow-up have the
lowest endpoint-free survival.
Renal function may act as a “barometer” of the severity of
CHF.27,28 However, because of the multifactorial nature of cardio-
renal interactions, merely assessing the glomerular function may be
suboptimal for decision-making. Our study confirms this and provides
additional evidence for the notion that each aspect of the kidney (glo-
merular and tubular) provides incremental prognostic information, and
together they may further identify higher-risk CHF individuals. These
kidney-specific signals may therefore help physicians to better and
timely target medical therapy before the future event occurs.
Based on our findings, we could speculate that “renoprotective”
treatment targeted at the tubules may be even more effective than treat-
ment simply aiming at improving only eGFR or Cr values. To this end, we
have previously found that higher ACE-inhibitor/ARBs doses during
follow-up were associated with less renal tubular damage together with
less cardiac impairment (as assessed by NT-proBNP and troponin
levels).29 However, interventional studies on these tubular damage
markers are needed to provide definite answers in this matter.
Our findings suggest that patients who have reduced eGFR already
at baseline are more susceptible to tubular injury during follow-up than
those with higher baseline eGFR (ie, greater renal functional capacity).
This phenomenon may potentially be attributed to the “work-overload”
in residual nephrons to compensate renal function in patients who had
fewer functioning nephrons available.30 Compensatory hyperfiltration in
the rest of nephrons may eventually exceed tubular adaption to hypo-
perfusion leading to tubulointerstitial hypoxic damage.31,32 These intrin-
sic adaptations of tubules and peritubular capillaries to renal injury have
been recognized as important factors for glomerulotubular balance to
parallel glomerular filtration rate of a nephron.33
Moreover, these patients more frequently had diabetes which, on its
part, may also have contributed to tubular injury. Similarly, other clinical
determinants such as aging kidneys and severity of HF (higher cardiac
markers and NYHA class, lower LV ejection fraction, and CRT) suggest
that factors that are related to more severe HF also cause tubule-specific
renal injury. Importantly, renal tubular biomarkers entailed unfavorable
outcomes even in patients with apparently stable glomerular function
during follow-up. Thus, the rise in urinary tubular biomarkers may indi-
cate subclinical renal impairment even before renal function itself
declines. Finally, our findings suggest that simultaneous assessment
of NAG and KIM-1 translates into better risk stratification in terms of
survival rates than assessment of either marker alone.
Higher doses of loop diuretics and lower MRA doses were iden-
tified in patients with WRF and are supported by previous stud-
ies.1,34 WRF was found to be associated with higher baseline eGFR
which is also supported by several previous studies.35-37 However,
this finding is inconsistent with the general opinion that WRF
(defined as delta Cr >0.03 mg/dL) occurs more frequently in CHF
patients that have impaired GFR already at baseline.38 One explana-
tion for this discrepancy may be that closer monitoring of patients
who already had impaired GFR could have also increased the likeli-
hood of finding WRF in these patients,34 and particularly if sampling
was not fixed but left at the discretion of the treating physician.39 As
for our study, the observations were made using more than twice as
many repeated measurements as in each of the previous studies,
samples were collected prospectively at fixed time intervals defined
by the study protocol. This further strengthens our suggestion that
WRF should not be disregarded in CHF patients with relatively intact
renal function.
Several limitations merit consideration. First, this study lacked
direct GFR measurement. Second, we cannot comment on the effects
of glomerular permeability on clinical outcomes since proteinuria was
not measured. Third, causal inference is limited by the observational
nature of our study. Although trials on this subject are still lacking, the
repeated-measures design of this study allows for stronger claims of
true associations than previous studies do.
5 | CONCLUSIONS
Slopes of tubular damage andWRF biomarkers had different clinical deter-
minants. Both predicted clinical outcome, but this associationwas stronger
for tubular injury. Prognostic effects of both appeared independent and
additive. These findings are of particular interest since in current clinical
practice the degree of tubular injury usually remains undetermined.
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